Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT ... low and intermediate risk prostate cancer (PCa) without specifically ...

Eligible patients had bulky (5 × 5 cm) tumors (T2-4) with or without pelvic lymph node involvement according to the 1988 American Joint Committee on Cancer TNM staging system. Patients received ...

Our findings indicate that the combination of neoadjuvant docetaxel with androgen-deprivation therapy before radical prostatectomy should not be considered as a treatment option for men with ...

A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for ... including Lupron ...

Hormonal treatments, called androgen suppression therapy, reduce the amounts or potency of certain hormones to slow the development of prostate cancer. Nonhormonal treatments try to remove or kill ...

“We believe that Fast-Track designation for SYNC-T SV-102 will significantly aid our development goals for this therapy for men with difficult-to-treat prostate cancer,” said Charles ...